VYNE Investor Relations Presentation
VYNE-Investor-Presentation
VYNE-Investor-Presentation
KOL Event – Novel InhiBET BET Inhibitor Platform
Notice of Effectiveness
Annual report [Section 13 and 15(d), not S-K Item 405]
Registration statement under Securities Act of 1933
Securities to be offered to employees in employee benefit plans
2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional investors Anticipate commencing a Phase 2b trial for VYN201 and a Phase 1a trial for VYN202 in Q2 2024 Ended 2023 with $93.3 million of cash, cash equivalents, restricted cash and marketable securities, providing runway through the end of 2025 and multiple expected clinical milestones BRIDGEWATER, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated…